TOUCH, The Black Breast Cancer Alliance (TOUCHBBCA)—in collaboration with the Triple Negative Breast Cancer Foundation, the ...

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...

Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

With FDA approval in the bag for its AI-based aortic stenosis diagnostic tool, Echo IQ is focused on commercialisation over the coming years.

An update from the PURPOSE 2 trial focused on adherence and pharmacokinetics data for lenacapavir, used to prevent HIV.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $84.00.

AUSTIN, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s ...

The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...

This report explores the benefits and challenges of NHS-industry partnerships aiming to catalyse improvements in the health ...

STEM South West is back for its sixth year, promising to be the biggest and best one yet - this time taking over Cork City ...